Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial
Emaus N, Gjesdal CG, Almås B, Christensen M, Grimsgaard AS, Berntsen GK, Salomonsen L, Fønnebø V
Published in Osteoporosis International
Methodology
Twelve-month randomised, double-blind, placebo-controlled trial of menaquinone-7 360 mcg/day in 334 healthy early-menopausal Norwegian women.
Key Findings
No significant difference in bone mineral density change at any measured site despite improved vitamin K status markers.
Conclusions
Vitamin K2 supplementation did not influence bone loss in early menopausal women over one year.
Limitations
Twelve-month duration may be too short for BMD change; healthy replete population.
Supplements Studied
Vitamin K2 supplementation did not influence bone loss in early menopausal women over 12 months.
No significant difference in bone mineral density change at any measured site despite improved vitamin K status markers.
Outcomes Measured
No significant difference in bone mineral density change at any site with vitamin K2.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.